TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$5.63 USD
-0.01 (-0.18%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.66 +0.03 (0.53%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for TScan Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -89.22 | -66.22 | -48.63 | -26.13 | -13.66 |
Depreciation/Amortization & Depletion | 5.36 | 5.14 | 3.33 | 1.23 | 0.52 |
Net Change from Assets/Liabilities | 17.61 | -10.23 | -5.90 | 21.36 | 0.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.89 | 4.81 | 2.52 | 0.52 | 0.32 |
Net Cash From Operating Activities | -61.36 | -66.50 | -48.68 | -3.02 | -12.52 |
Property & Equipment | -3.15 | -4.23 | -9.94 | -4.24 | -1.25 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -57.61 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -60.76 | -4.23 | -9.94 | -4.24 | -1.25 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 135.44 | 0.33 | 189.67 | 0.29 | 34.81 |
Issuance (Repayment) of Debt | 0.00 | 29.35 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.32 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 135.44 | 29.36 | 189.67 | 0.29 | 34.81 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 13.33 | -41.37 | 131.05 | -6.97 | 21.04 |
Cash at Beginning of Period | 125.06 | 166.44 | 35.39 | 42.36 | 21.32 |
Cash at End of Period | 138.39 | 125.06 | 166.44 | 35.39 | 42.36 |
Diluted Net EPS | -1.36 | -2.75 | -4.17 | -28.52 | NA |
Fiscal Year End for TScan Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -61.80 | -30.14 | -89.22 | -69.61 | -46.61 |
Depreciation/Amortization & Depletion | 2.37 | 1.25 | 5.36 | 4.08 | 2.80 |
Net Change from Assets/Liabilities | 0.07 | -2.11 | 17.61 | 23.80 | -4.60 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.87 | 1.73 | 4.89 | 4.13 | 2.80 |
Net Cash From Operating Activities | -55.49 | -29.27 | -61.36 | -37.59 | -45.61 |
Property & Equipment | -1.57 | -0.71 | -3.15 | -2.68 | -1.26 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.01 | 36.87 | -57.61 | -60.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 2.45 | 36.16 | -60.76 | -62.67 | -1.26 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 161.85 | 0.26 | 135.44 | 135.42 | 135.68 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 92.39 |
Net Cash from Financing Activities | 161.85 | 0.26 | 135.44 | 135.42 | 135.68 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 108.80 | 7.15 | 13.33 | 35.16 | 88.81 |
Cash at Beginning of Period | 138.39 | 138.39 | 125.06 | 125.06 | 125.06 |
Cash at End of Period | 247.19 | 145.54 | 138.39 | 160.22 | 213.87 |
Diluted Net EPS | -0.28 | -0.32 | 0.32 | -0.24 | -0.51 |